ArticleMathematical biosciences2022
Optimal control of the SIR model with constrained policy, with an application to COVID-19.
Article in Mathematical biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article considers the optimal control of the SIR model with both transmission and treatment uncertainty. It follows the model presented in Gatto and Schellhorn (2021). We make four significant improvements on the latter paper. First, we prove the existence of a solution to the model. Second, our interpretation of the control is more realistic: while in Gatto and Schellhorn (2021) the control α is the proportion of the population that takes a basic dose of treatment, so that α>1 occurs only if some patients take more than a basic dose, in our paper, α is constrained between zero and one, and represents thus the proportion of the population undergoing treatment. Third, we provide a complete solution for the moderate infection regime (with constant treatment). Finally, we give a thorough interpretation of the control in the moderate infection regime, while Gatto and Schellhorn (2021) focused on the interpretation of the low infection regime. Finally, we compare the efficiency of our control to curb the COVID-19 epidemic to other types of control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.